Markets.com Logo
markets.com

IMUX

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    --
  • Previous Close
    --
  • 52 Week Change
    --
  • Day Range
    --
  • 52 Week High/Low
    --
  • Dividend Per Share
    --
  • Market cap
    --
  • EPS
    --
  • Beta
    --
  • Volume
    --

About

IMUX.US represents Immunic, Inc., a biopharmaceutical company focused on developing orally administered, selective immunotherapies for the treatment of chronic inflammatory and autoimmune diseases. Their lead product candidate, vidofludimus calcium, is in clinical development for multiple sclerosis and other autoimmune disorders. The company's research and development efforts primarily target the modification of the immune system to treat these conditions.
markets.com
Micron vs SanDisk: Which Stock Is Better Positioned for AI Growth?

Micron vs SanDisk: Which Stock Is Better Positioned for AI Growth?

Julian Parker|--
AMD vs Intel vs Arm: Which Stock Could Benefit Most From the AI Inference Boom?

AMD vs Intel vs Arm: Which Stock Could Benefit Most From the AI Inference Boom?

Daniel Carter|--
AMD Joins the $1 Trillion Club as AI Demand Lifts Shares: AI Chip Stock Forecast and Outlook

AMD Joins the $1 Trillion Club as AI Demand Lifts Shares: AI Chip Stock Forecast and Outlook

Julian Parker|--
British Pound Short-Term Outlook: Can GBP/USD Hold 1.33 as Fed–BoE Policy Divergence Widens?

British Pound Short-Term Outlook: Can GBP/USD Hold 1.33 as Fed–BoE Policy Divergence Widens?

Julian Parker|--
Stellar XLM Price Prediction 2026, 2027 & 2030: Can XLM Reach $1?

Stellar XLM Price Prediction 2026, 2027 & 2030: Can XLM Reach $1?

Daniel Carter|--

The energy sector remains a hot topic & precious metals

Darius Anucauskas|--
Dollar to Mexican Peso Forecast 2026–2030: Can USD/MXN Break Above 17.50 as the Rate Gap Narrows?

Dollar to Mexican Peso Forecast 2026–2030: Can USD/MXN Break Above 17.50 as the Rate Gap Narrows?

Julian Parker|--

Factors

Drug Pipeline Progress: Positive clinical trial results for I-Mab's drug candidates often lead to increased stock prices, while negative results can cause declines.

Regulatory Approvals: Approvals from regulatory bodies like the FDA for I-Mab's drugs are major catalysts for price increases.

Partnerships and Licensing Agreements: Deals with larger pharmaceutical companies to co-develop or market I-Mab's drugs can positively affect the stock.

Market Sentiment: Overall investor confidence in the biotechnology sector influences I-Mab's stock price.

Financial Performance: I-Mab's cash position, R&D spending, and revenue (if any) affect investor perceptions of its long-term viability.

Competition: The success of competing drugs or therapies targeting the same diseases can negatively impact I-Mab's stock.

People Also Watch

Latest news

Gold Price Today: Gold Holds Near $4,280 After Strong US PMI Sends Treasury Yields Higher

Gold Price Today: Gold Holds Near $4,280 After Strong US PMI Sends Treasury Yields Higher

Julian Parker|--
McDonald’s Stock Falls Nearly 5% as NEXT Investor Day Raises Turnaround Questions

McDonald’s Stock Falls Nearly 5% as NEXT Investor Day Raises Turnaround Questions

Julian Parker|--
Treasury Yields Spike After Strong US PMI as Nasdaq Falls More Than 1%

Treasury Yields Spike After Strong US PMI as Nasdaq Falls More Than 1%

Julian Parker|--

Latest Education Articles

Risk Management 101

Risk Management 101

Julian Parker|--
Best AI Stocks to Buy Now: 10 Best Performing AI Stocks to Watch in 2026

Best AI Stocks to Buy Now: 10 Best Performing AI Stocks to Watch in 2026

Julian Parker|--
Gold Scalping Strategy: How Scalping XAU/USD Works

Gold Scalping Strategy: How Scalping XAU/USD Works

Julian Parker|--
Recommended Topics
markets.com